Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
20–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically- or cytologically-proven diagnosis of breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent
Measurable disease as per RECIST. Measurable lesions that have been previously irradiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.
Prior treatment with an anthracycline and a taxane in the neoadjuvant, adjuvant or metastatic disease settings.
You may not be if
Histology of inflammatory carcinoma with no other measurable disease. Patients with histology of inflammatory carcinoma are allowed on study if they have measurable disease.
Brain metastases, spinal cord compression, or carcinomatous meningitis, or leptomeningeal disease.
Prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives such as Furtulon (5'-DFUR), Futraful/ Sunfural (tegafur), UFT/UFT-E (tegafur/uracil), TS-1 (tegafur/gimeracil/oteracil) or Mifurol (carmofur) in metastatic disease setting
Clareo Health | Study Of Sunitinib With Capecitabine In Breast Cancer
